Reed Hoffman Starts Manas Ai, a new startup for drug detection

Co -founder and risk capital LinkedIn Reed Hoffman became a billionaire from his business social company and made lucrative bets on companies, including Airbnb and zynga while supporting the launch of nuclear synthesis Helion energyS

Now Hoffman dives in healthcare, which he describes as “wonderful and terrifying” with his last Startup Manas Ai.

Hoffman and Dr. Siddhartha Mukerji, oncologist and author of Pulitzer Awards, discovered The company on Monday. Manas will use artificial intelligence to try to accelerate the drug detection process, starting with new treatments for aggressive cancers such as prostate cancer, lymphoma and triple-negative breast cancer.

Developing new drugs is traditionally an expensive and complex process. This may take more than 10 years and cost billions of dollars to develop a medicine according to a report from DELOITTES Manas said he would use his own chemical libraries and filters with AI power to identify drug candidates faster, ideally reducing the detection process for decades only a few years.

“Most people had friends, family members, etc. who died of cancer or had serious cancer problems,” Hoffman told CNBC in an interview this week. “If we can make a huge change in this and this is the species in which AI can make a huge change, this is the kind of AI can be great for humanity.”

Manas raised $ 24.6 million in funding for seeds led by Catalyst And Hoffman with participation from Grellock, where he is a partner. Hoffman has been deep in AI in recent years. He was an early investor at OpenAi when the project was still a non -profit purpose and helped start AI on flexion with Deepmind co -founder Mustafa Suleiman. Last year, Suleiman joined MicrosoftWhere Hoffman is a member of the board as the CEO of a new unit called Microsoft AI. Several fleet employees have joined him.

Manas also signed a partnership with MicrosoftAnd he will use his Azure cloud calculation platform. Hoffman, who sold LinkedIn to Microsoft for $ 27 billion, said Manas also had several additional instruments from Microsoft, including some that are not yet available to the public.

Hoffman has been working with Mukherjee to create Manas for about a year, although the process has taken steam over the past few months. Hoffman said the team felt ready to publicly share his ambitions this week as his main main resources were in order.

The company has a long way forward and the drug detection market is very competitive. Other start -ups together with large pharmaceutical companies such as Eli Lily., Pfizer and MercateThey are also exploring how to take advantage of AI to accelerate drug research and development.

Hoffman said he was feeling confident in Manas’s approach, though he would be “completely delighted” to see many companies flourish.

“We also carry something that a startup usually wears, which is a willingness to go very hard, to abandon things quickly that do not work,” he said. “Live like this week matters and the result of this week matters.”

After the launch of Manas on Monday, five different potential strategic partners have already turned to the company, Hoffman said.

Hoffman said the company is in the “Build Quick” mode and “Learn and unfold”. One of his early initiatives is called Project Cosmos, which is an effort to outline the basic rules for binding drugs, according to the company’s website. Hoffman declined to share additional details about the project.

Currently, Manas has only four employees – including Hoffman and Mukerji – but Hoffman said he would grow. It acts as the “AI man” of the company, while Mukherjee serves as a “organic man,” he said. In the end, Manas is for the overturn of both fields.

“It’s not just the best of science and it’s not just the best of AI, because none of these two is insufficient,” Hoffman said. “You have to collect these two.”

So

Deepseek started generating Buzz in January when the launch launched its open code reasoning model, which rivals OPAI on O1. The model has been reported to have been developed with part of the price of competitive Openai, Anthrop, Google and others.

Hoffman said that while Deepseek can encourage US companies to pick up the pace and share their plans earlier, new revelations do not suggest that big models are a bad investment.

“The game of the race is included,” he said, “but I don’t think it’s” Oh God, we lose! “as American technology.”

Watch: LinkedIn RED Hoffman’s co -founder of Deepseek